Welcome to our dedicated page for Arcadia Bioscien news (Ticker: RKDA), a resource for investors and traders seeking the latest updates and insights on Arcadia Bioscien stock.
Arcadia Biosciences, Inc. (Nasdaq: RKDA) regularly issues news and updates as a producer and marketer of plant-based and innovative wellness products. With its roots in agricultural innovation and a current focus on Zola coconut water and related wellness offerings, the company’s announcements provide insight into its operating performance, strategic direction, and capital markets activity.
News items for RKDA often include quarterly and annual financial results, where Arcadia reports revenue trends, gross margin performance, and changes in operating expenses. These releases detail how Zola coconut water revenues and distribution have evolved over time, and how asset sales, credit losses, and fair value changes in financial instruments have affected net income or loss attributable to common stockholders.
Arcadia’s news flow also covers strategic transactions and corporate actions. Examples include the sale of its GoodWheat brand and wheat-related intellectual property, agreements to transfer or terminate certain patent rights, and the previously announced but later terminated proposed business combination with Roosevelt Resources, LP. Press releases describe the rationale for these actions and their role in streamlining operations and evaluating strategic alternatives.
Investors following RKDA news will also see capital-raising and securities-related announcements, such as inducement transactions involving preferred investment options and the issuance of new options and placement agent options, as disclosed in company filings and related press releases. In addition, Arcadia publishes notices about upcoming earnings releases, conference calls, and virtual stockholder meetings, along with proxy and governance information.
This news page aggregates these disclosures so readers can review Arcadia’s earnings reports, transaction updates, financing developments, and governance communications in one place. For those tracking RKDA, the feed offers a structured view of how the company describes its business focus, financial condition, and strategic plans over time.
Arcadia Biosciences (Nasdaq: RKDA) agreed to immediate exercises of certain preferred investment options to purchase up to 808,595 shares at a reduced exercise price of $2.575 per share, generating approximately $2.1 million gross proceeds before fees. In exchange, Arcadia will issue new unregistered preferred investment options to buy up to 1,617,190 shares at an exercise price of $2.325, exercisable immediately and expiring 30 months after the Resale Registration Statement effective date. The offering is expected to close on or about January 12, 2026, with H.C. Wainwright & Co. as placement agent.
Net proceeds are intended for working capital and general corporate purposes.
Arcadia Biosciences (Nasdaq: RKDA) said it received a termination notice from Roosevelt Resources on December 24, 2025, ending the Securities Exchange Agreement dated December 4, 2024 for a proposed business combination.
The company said it will resume evaluating strategic alternatives to create shareholder value. Management noted operational streamlining, reduced operating expenses, growth of the Zola coconut water brand, and avoidance of long-term debt over the past two-and-a-half years. Arcadia also reported it continues to own approximately 2.7 million shares of Above Food Ingredients common stock and stated it believes it is entitled to additional consideration relating to its May 2024 sale of GoodWheat.
Arcadia Biosciences (Nasdaq: RKDA) reported third quarter 2025 results on Nov 7, 2025 showing mixed operating performance and balance sheet activity.
Zola year-to-date revenue rose 26% driven by increased distribution; third-quarter revenues were flat year‑over‑year. Gross profit margins exceeded 30% for the 11th consecutive quarter. Cash declined by $257K to $1.1M. The company recognized a $4.7M credit loss2.7M shares of Above Food Ingredients as partial repayment.
Arcadia Biosciences (NASDAQ:RKDA) reported Q2 2025 financial results, with total revenues increasing 11% year-over-year to $1.46 million, driven by 24% growth in Zola® coconut water sales. The company maintained gross margins above 30% for ten consecutive quarters.
Key developments include receiving 2.7 million shares of Above Food Ingredients (ABVE) stock as partial repayment of a $6 million note receivable from the GoodWheat™ assets sale, and eliminating $1 million in contingent liabilities through an agreement with Bioseed Research India. However, the company recognized a $4.5 million credit loss related to the Above Food note receivable.
Q2 2025 resulted in a net loss of $4.46 million ($3.26 per share), compared to net income of $1.06 million in Q2 2024. The company's pending business combination with Roosevelt Resources continues to progress with an amended Form S-4 registration statement filed.
Arcadia Biosciences (Nasdaq: RKDA), a producer and marketer of plant-based health and wellness products, has scheduled its first quarter 2025 financial results announcement for May 8, 2025.
The company will host a conference call at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss their Q1 results and key strategic achievements. Investors and interested parties can participate through two options:
- An audio-only webcast available through the Investors section of Arcadia's website
- Live call participation by registering online to receive a dial-in number and unique PIN
A recorded replay of the conference call will be made available in the Investors Section of the company's website following the event.
Arcadia Biosciences (RKDA) reported strong financial results for Q4 and full-year 2024, with year-over-year revenues growing 56% in Q4 and 13% for the full year. The company's Zola® coconut water brand showed exceptional performance with 124% revenue growth in Q4 and 46% for the full year.
Key developments include a planned business combination with Roosevelt Resources, where Roosevelt partners will own approximately 90% of Arcadia post-merger. The company also completed strategic asset sales, including the $4 million sale of its Resistant Starch Durum trait to Corteva Agriscience and the $4 million sale of GoodWheat brand to Above Food Corp.
Financial highlights show Zola's retail distribution nearly doubled in 2024, contributing to a $611,000 increase in Q4 coconut water revenue. The company reported a net loss of $4.1 million ($2.98 per share) in Q4 2024, compared to $2.8 million ($2.10 per share) in Q4 2023.
Arcadia Biosciences (RKDA), a producer and marketer of innovative, plant-based health and wellness products, has scheduled its fourth quarter and full year 2024 financial results announcement for March 20, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss Q4 and year-end results along with key strategic achievements. Investors can participate through an audio-only webcast available on Arcadia's website or join the live call through registration for a dial-in number and unique PIN.
Arcadia Biosciences (RKDA) has entered into a definitive securities exchange agreement with Roosevelt Resources LP for an all-stock business combination. Under the agreement terms, current Roosevelt equity owners will own approximately 90% of Arcadia's outstanding shares, while current Arcadia shareholders will retain about 10%.
Roosevelt Resources is a Dallas-based oil and gas company with a primary asset consisting of a 16,208-acre carbon capture utilization and storage (CCUS) project in the Texas Permian Basin. The project has estimated proved undeveloped reserves of 780 million gross boe and proved developed producing reserves of 3.8 million gross boe. Roosevelt plans to develop this as an enhanced oil recovery project over 40+ years, targeting peak production of 55,000 gross boepd by 2051.
Arcadia Biosciences (RKDA) announced its Q3 2024 financial results, reporting a notable 18% increase in total revenues compared to Q3 2023. The company highlighted a significant 55% growth in Zola coconut water revenues and a 68% expansion in Zola's retail distribution year over year. Operating expenses for Q3 2024 rose by $602,000, driven by higher revenues and employee severance costs. However, for the first nine months of 2024, operating expenses decreased by $3.4 million due to a $4.0 million gain from an asset sale to Corteva. Net loss attributable to common stockholders improved to $1.6 million for Q3 2024 from $2.6 million in Q3 2023, and for the first nine months of 2024, it decreased to $3.0 million from $11.1 million in the same period in 2023. The company attributes this improvement to decreased net loss from discontinued operations and the gain from the asset sale.
FAQ
What is the current stock price of Arcadia Bioscien (RKDA)?
What is the market cap of Arcadia Bioscien (RKDA)?
